Sciencast Management LP Invests $998,000 in Royalty Pharma plc (NASDAQ:RPRX)

Sciencast Management LP purchased a new stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 39,132 shares of the biopharmaceutical company's stock, valued at approximately $998,000.

Several other hedge funds and other institutional investors have also bought and sold shares of RPRX. Brooklyn Investment Group increased its stake in Royalty Pharma by 1,006.9% in the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 876 shares in the last quarter. Allworth Financial LP increased its position in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 877 shares in the last quarter. Riverview Trust Co increased its position in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares in the last quarter. Fifth Third Bancorp raised its stake in Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 997 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 376 shares in the last quarter. Institutional investors own 54.35% of the company's stock.

Remove Ads

Royalty Pharma Stock Up 0.3 %

Shares of RPRX stock traded up $0.09 during trading hours on Thursday, hitting $31.65. 7,555,002 shares of the company were exchanged, compared to its average volume of 2,917,036. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business has a 50 day moving average of $32.42 and a two-hundred day moving average of $28.80. The company has a market capitalization of $18.24 billion, a PE ratio of 21.83, a PEG ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date was Friday, February 21st. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's dividend payout ratio (DPR) is currently 60.69%.

Analysts Set New Price Targets

Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma currently has a consensus rating of "Buy" and an average target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.